代谢组学特征可区分系统性硬化相关肺动脉高压与特发性肺动脉高压,并与功能能力恶化相关
本研究比较了400例SSc-PAH与1082例IPAH患者的血浆生物活性脂质代谢物,并用100例无PH的硬皮病患者和44例硬皮病合并PH患者进行外部验证。通过液相色谱/高分辨质谱检测700余种代谢物,发现5种代谢物可区分SSc-PAH与IPAH并与疾病严重程度相关。SSc-PAH患者中脂肪酸代谢物(如木焦油酸和神经酸)、类花生酸/氧化脂质及性激素代谢物水平升高,提示其代谢谱不利,可能解释治疗反应较差。
要点
- SSc-PAH与IPAH患者存在5种可区分的循环生物活性脂质代谢物。
- SSc-PAH患者脂肪酸、类花生酸/氧化脂质及性激素代谢物水平相对升高。
- 上述代谢物差异与疾病严重程度标志物相关,提示代谢谱可解释临床差异。
核心结论
- SSc-PAH患者具有不利的生物活性代谢谱,可能解释其治疗反应差且有限。
研究设计与样本
- 研究纳入400例SSc-PAH和1082例IPAH患者血浆样本,另用100例无PH的硬皮病患者和44例硬皮病合并PH患者进行外部验证。
- 采用液相色谱/高分辨质谱检测700余种生物活性脂质代谢物,并用回归分析识别差异代谢物及其与疾病严重程度的关系。
主要发现
- 从数百种循环生物活性脂质中识别出5种代谢物可区分SSc-PAH与IPAH,并与疾病严重程度标志物相关。
- 与IPAH相比,SSc-PAH患者脂肪酸代谢物(包括木焦油酸和神经酸)、类花生酸/氧化脂质及性激素代谢物水平升高。
临床怎么用
- 对SSc-PAH患者可关注特定脂质代谢物谱,辅助理解其与IPAH的临床差异及治疗反应不佳的潜在机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The prognosis and therapeutic responses are worse for pulmonary arterial hypertension associated with systemic sclerosis (SSc-PAH) compared with idiopathic pulmonary arterial hypertension (IPAH). This discrepancy could be driven by divergence in underlying metabolic determinants of disease. RESEARCH QUESTION: Are circulating bioactive metabolites differentially altered in SSc-PAH vs IPAH, and can this alteration explain clinical disparity between these PAH subgroups? STUDY DESIGN AND METHODS: Plasma biosamples from 400 patients with SSc-PAH and 1,082 patients with IPAH were included in the study. Another cohort of 100 patients with scleroderma with no PH and 44 patients with scleroderma with PH was included for external validation. More than 700 bioactive lipid metabolites, representing a range of vasoactive and immune-inflammatory pathways, were assayed in plasma samples from independent discovery and validation cohorts using liquid chromatography/high-resolution mass spectrometry-based approaches. Regression analyses were used to identify metabolites that exhibited differential levels between SSc-PAH and IPAH and associated with disease severity. RESULTS: From hundreds of circulating bioactive lipid molecules, five metabolites were found to distinguish between SSc-PAH and IPAH, as well as associate with markers of disease severity. Relative to IPAH, patients with SSc-PAH carried increased levels of fatty acid metabolites, including lignoceric acid and nervonic acid, as well as eicosanoids/oxylipins and sex hormone metabolites. INTERPRETATION: Patients with SSc-PAH are characterized by an unfavorable bioactive metabolic profile that may explain the poor and limited response to therapy. These data provide important metabolic insights into the molecular heterogeneity underlying differences between subgroups of PAH.
引用
- Alotaibi M, Shao J, Pauciulo MW, et al. Metabolomic Profiles Differentiate Scleroderma-PAH From Idiopathic PAH and Correspond With Worsened Functional Capacity. Chest. 2022. PMID: 36087794. doi:10.1016/j.chest.2022.08.2230
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。